Last reviewed · How we verify
Early Vasopressin
Early Vasopressin is a Vasopressor agent Small molecule drug developed by Hospital do Coracao. It is currently in Phase 3 development for Acute hypotension and distributive shock (septic shock, post-operative hypotension), Variceal bleeding with hypotension.
Early Vasopressin is a vasopressin analog that acts as a vasoconstrictor to increase blood pressure and peripheral vascular resistance in acute hypotensive states.
Early Vasopressin is a vasopressin analog that acts as a vasoconstrictor to increase blood pressure and peripheral vascular resistance in acute hypotensive states. Used for Acute hypotension and distributive shock (septic shock, post-operative hypotension), Variceal bleeding with hypotension.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Early Vasopressin |
|---|---|
| Sponsor | Hospital do Coracao |
| Drug class | Vasopressor agent |
| Target | V1 receptor |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Vasopressin (antidiuretic hormone) binds to V1 receptors on vascular smooth muscle cells, causing vasoconstriction and increased systemic vascular resistance. This mechanism is used in acute care settings to restore blood pressure in patients with distributive shock or severe hypotension refractory to fluid resuscitation and catecholamines.
Approved indications
- Acute hypotension and distributive shock (septic shock, post-operative hypotension)
- Variceal bleeding with hypotension
Common side effects
- Peripheral vasoconstriction / ischemia
- Hyponatremia
- Cardiac arrhythmias
- Mesenteric ischemia
Key clinical trials
- CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial (PHASE2)
- Early Versus Late Adjunctive Vasopressin in Septic Shock (PHASE4)
- Norepinephrine and Vasopressin for Rescue Versus Early Vasopressin for Vasopressor Dependent Sepsis (PHASE3)
- Efficacy of Early Argipressin in the Management of Intensive Care Patients With Norepinephrine-refractory Vasoplegic Shock (PHASE3)
- Multimodal Vasopressor Strategy in Septic Shock (PHASE2, PHASE3)
- Renal Outcomes in the Early Use of Vasopressin in the Treatment of Septic Shock (PHASE4)
- Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients (PHASE4)
- Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Early Vasopressin CI brief — competitive landscape report
- Early Vasopressin updates RSS · CI watch RSS
- Hospital do Coracao portfolio CI
Frequently asked questions about Early Vasopressin
What is Early Vasopressin?
How does Early Vasopressin work?
What is Early Vasopressin used for?
Who makes Early Vasopressin?
What drug class is Early Vasopressin in?
What development phase is Early Vasopressin in?
What are the side effects of Early Vasopressin?
What does Early Vasopressin target?
Related
- Drug class: All Vasopressor agent drugs
- Target: All drugs targeting V1 receptor
- Manufacturer: Hospital do Coracao — full pipeline
- Therapeutic area: All drugs in Critical Care / Cardiovascular
- Indication: Drugs for Acute hypotension and distributive shock (septic shock, post-operative hypotension)
- Indication: Drugs for Variceal bleeding with hypotension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing